Post-registration trials of the Russian vaccine against coronavirus – Sputnik V – prepared at the Gamaleya National Research Centre for Epidemiology and Microbiology in Russia will begin in Moscow next week, the city’s mayor, Sergey Sobyanin, said Friday. In the Phase 1 and 2 studies of the vaccine. participants developed antibodies to the virus that causes Covid-19, were similar to the immune response that people had after naturally recovering from Covid-19. There were also responses from T cells, which are part of the immune system. In the study, half of the participants developed fevers and 42% developed headaches. In addition, about 28% experienced weakness and 24% had joint pain. It was not said how long these side effects lasted.
Gamaleya is using adenoviruses in their Covid-19 vaccines; this is the same approach used in the vaccine developed by the University of Oxford and AstraZeneca. The Gamaleya vaccine is given in two doses, and each dose uses a different adenovirus vector. More than 5,000 people have already signed up to participate in the trials. Polls suggest however around half of Russian citizens are skeptical about the vaccine. In the world, China approved an experimental coronavirus vaccine in June for members of its military, and in August, it emerged the country had been using the vaccine on those in “high risk” professions.